While many studies have shown a critical role of the IL-33/ST2 signaling in inflammatory lung disease, including respiratory allergy, asthma, and chronic obstructive lung disease (19, 40–42), few have investigated the contribution of this pathway to lung cancer. This evidence concerns the gene IL33 and lung carcinoma.